By analysing 4871 different tumour samples, the co-occurrence of genetic abnormalities has been found in the majority of RET- altered patients (81.8%, 72/88 patients), the most common being TP-53 associated genes (59.1%, 52/88 patients), cell cycle-associated genes (39.8%, 35/88 patients), the PI3K signalling pathway (30.7%, 27/88 patients), MAPK effectors (22.7%, 20/88 patients) or other tyrosine kinase families (21.6%, 19/88 patients) such as FGFR families, EGFR, ALK, HER2, PDGFRα and PDGFRβ [6]. Here, ALK is linked to neoplasm.